Aug 14, 2020 2:25pm EDT Lantern Pharma Interview to Air on Bloomberg International on the RedChip Money Report
Jul 30, 2020 6:57am EDT Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
Jul 24, 2020 7:56am EDT Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020
Jul 20, 2020 7:55am EDT Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma
Jun 29, 2020 8:45am EDT Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Data Points, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Data Points Curated Specifically for Oncology Drug Development and Drug Response Prediction
Jun 17, 2020 9:23am EDT Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
Dec 17, 2019 8:30am EST Lantern Pharma Appoints David Margrave as Chief Financial Officer and Kishor Bhatia, Ph.D., as Chief Scientific Officer
